Adverum Biotechnologies to Join TD Cowen's Genetic Medicines & RNA Summit

June 18, 2024-- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company dedicated to the development of gene therapy for ocular diseases, announced that its president and CEO, Laurent Fischer, M.D., will participate in a fireside chat at TD Cowen’s Genetic Medicines & RNA Summit on June 21, 2024, at 10:00 a.m. ET. The presentation will be available via webcast on Adverum’s website under the Investors section, with a replay accessible for at least 30 days post-event.

Adverum Biotechnologies is focused on establishing gene therapy as a new treatment standard for prevalent ocular diseases, aiming to develop therapies that can restore vision and prevent blindness. Utilizing its proprietary intravitreal (IVT) platform, Adverum is creating durable, single-administration therapies that are designed to be administered in physicians' offices, thereby reducing the need for frequent eye injections.

The company's lead gene therapy candidate, ixoberogene soroparvovec, also known as Ixo-vec (formerly ADVM-022), is being evaluated for its potential to treat neovascular or wet age-related macular degeneration through a one-time IVT injection. By addressing the limitations of current treatments for serious ocular diseases, Adverum aims to revolutionize the standard of care, preserve vision, and create a significant societal impact globally.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!